Clinical trial
Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer
NCT00475657 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00475657 |
|---|---|
| Title | Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer |
| Official title | Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, cisplatin |
| Enrollment | 5 |
| Start date | Oct 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 21, 2007 |
| Last update posted | May 29, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: